End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump ...

Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...

SK bioscience announced on the 14th that it has begun supplying the antibody injection for respiratory syncytial virus (RSV) prevention called "Beyfortus" from the French company Sanofi. Beyfortus can ...

Beyfortus needs two injections but, on the other hand, is also approved for use in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Vaccines are designed to guard babies, toddlers, and older children against a whole range of serious and potentially deadly ...

The panel voted 21 to zero that Beyfortus (nirsevimab) appears to be safe and effective at preventing RSV infections in newborns and infants as they face their first RSV season, setting the drug ...

Therapeutics Market Growth is Driven by Increased Awareness of RSV’s Health Risks and The Development of Advanced Treatment Options.Pune, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Respiratory Syncytial Virus ...

This narrowing results from swelling caused by a virus. The respiratory syncytial virus (RSV) causes most bronchiolitis. RSV occurs in epidemics almost every winter. People do not develop life-long ...

This narrowing results from swelling caused by a virus. The respiratory syncytial virus (RSV) causes most bronchiolitis. RSV occurs in epidemics almost every winter. People do not develop life-long ...

CTV National News: Finding the origin of COVID-19 Allison Bamford has the latest on the new findings from a team of scientists, including a virologist from Sask., into the origins of COVID.